Nearly Half of New Semaglutide and Tirzepatide Weight-Loss Users Stayed on Low Doses Through Their First Six Months
An observational study found that nearly half of new semaglutide and tirzepatide users remained on low doses during six months, potentially reflecting tolerability, cost, access or prescribing decisions.
Medical Daily ·